Follow
Sabiha Parveen
Sabiha Parveen
Ph.D., Aligarh Muslim University & former exchange research fellow at The Ohio State
Verified email at amu.ac.in
Title
Cited by
Cited by
Year
Organo-tin antitumor compounds: Their present status in drug development and future perspectives
F Arjmand, S Parveen, S Tabassum, C Pettinari
Inorganica Chimica Acta 423, 26-37, 2014
1182014
Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action
S Parveen, F Arjmand, S Tabassum
European Journal of Medicinal Chemistry 175, 269-286, 2019
442019
Recent advances in metallodrug-like molecules targeting non-codingRNAs in cancer chemotherapy
FA Zeenat Afsan, Surbhi Sharma, Sabiha Parveen, Imtiyaz Yousuf, Sara Sartaj ...
Coordination Chemistry Reviews 387, 47-59, 2019
252019
Synthesis of chiral R/S-pseudopeptide-based Cu (II) & Zn (II) complexes for use in targeted delivery for antitumor therapy: enantiomeric discrimination with CT-DNA and pBR322 …
S Parveen, S Tabassum, F Arjmand
RSC advances 7 (11), 6587-6597, 2017
242017
Synthesis and characterization of Co (II) and Fe (II) peptide conjugates as hydrolytic cleaving agents and their preferential enantiomeric disposition for CT-DNA: structural …
S Parveen, M Usman, S Tabassum, F Arjmand
RSC advances 5 (88), 72121-72131, 2015
202015
Human topoisomerase I mediated cytotoxicity profile of l-valine-quercetin diorganotin (IV) antitumor drug entities
S Parveen, S Tabassum, F Arjmand
Journal of Organometallic Chemistry 823, 23-33, 2016
172016
Copper (II) L/D-valine-(1, 10-phen) complexes target human telomeric G-quadruplex motifs and promote site-specific DNA cleavage and cellular cytotoxicity
F Arjmand, S Sharma, S Parveen, L Toupet, Z Yu, JA Cowan
Dalton Transactions 49 (28), 9888-9899, 2020
152020
Enantiomeric copper based anticancer agents promoting sequence-selective cleavage of G-quadruplex telomeric DNA and non-random cleavage of plasmid DNA
S Parveen, JA Cowan, Z Yu, F Arjmand
Metallomics 12 (6), 988-999, 2020
142020
New Ionic Cu(II) and Co(II) DACH–Flufenamate Conjugate Complexes: Spectroscopic Characterization, Single X–Ray Studies and Cytotoxic Activity on Human Cancer Cell Lines
FA Huzaifa Yasir Khan, Siffeen Zehra,Sabiha Parveen,Imtiyaz Yousuf, Sartaj ...
ChemistrySelect 3, 12764– 12772, 2018
122018
Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: Mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of COX–1 and COX–2 …
HY Khan, S Parveen, I Yousuf, S Tabassum, F Arjmand
Coordination Chemistry Reviews 453, 214316, 2022
102022
RNA-targeted Cu (II)-based potential antitumor drug entity: Comprehensive structural, biological {DNA/RNA binding, cleavage, cytotoxicity} and computational studies
S Parveen, K Fatima, S Zehra, F Arjmand
Journal of Biomolecular Structure and Dynamics 39 (16), 6070-6083, 2021
102021
Elucidating the interaction of enantiomeric Cu (II) complexes with DNA, RNA and HSA: A comparative study
S Parveen, S Jafri, HY Khan, S Tabassum, F Arjmand
Polyhedron 210, 115501, 2021
52021
Interaction of Carrier Protein with Potential Metallic Drug Candidate N-Glycoside ‘GATPT’: Validation by Multi-Spectroscopic and Molecular Docking Approaches
ST Sabiha Parveen, Mohd. Sajid Ali, Hamad A. Al-Lohedan
Molecules 26, 6641., 2021
12021
Molecular interaction of lysozyme with therapeutic drug azithromycin: Effect of sodium dodecyl sulfate on binding profile
S Parveen, MS Ali, HA Al-Lohedan, N Hoti, S Tabassum
International Journal of Biological Macromolecules, 124844, 2023
2023
Protective effects of a polyherbal medicine, Majoon Suranjan against bisphenol-A induced genetic, oxidative and tissue damages
D Singh, MA Khan, K Akhtar, S Rehman, S Parveen, KMY Amin, ...
Drug and Chemical Toxicology, 1-13, 2022
2022
Chiral discrimination of metal–based chemotherapeutics Co(II), Cu(II) and Zn(II) towards the ultimate drug target–DNA
MA Farukh Arjmand, Shazia Parveen, Sabiha Parveen
Chemistry & Biology Interface 3 (3), 137-145, 2013
2013
The system can't perform the operation now. Try again later.
Articles 1–16